Lilly reports broader biomarker changes with combination

Roche, Novartis, Pfizer, and Eli Lilly received FDA approvals for their drugs. Lupin and Lipocine also gained regulatory nods. Caribou Biosciences plans to cut workforce and discontinue programs. Several biopharma companies announced deals and partnerships. Stock prices for mentioned companies varied.

Eli Lilly's phase 3b TOGETHER-PsO trial showed its combination treatment of Taltz and Zepbound improved outcomes for patients with moderate-to-severe plaque psoriasis who are overweight or obese. The company's GF Value™ suggests it is modestly undervalued with a 25.4% margin of safety, and its GF Score™ is 98 out of 100, indicating strong financial health. Insiders have been net sellers, while 25 premium gurus hold LLY, with 12 adding and 10 trimming positions.

Eli Lilly presented data from the TOGETHER-PsO Phase 3b trial showing that combining Taltz (ixekizumab) and Zepbound (tirzepatide) led to broader biomarker responses in adults with psoriasis and obesity compared to Taltz alone. The trial, presented at the 2026 Fall Clinical Dermatology Conference, found greater reductions in inflammatory immune activity with the combination treatment.

Eli Lilly (LLY) presented data from its Phase 3b TOGETHER-PsO trial, showing that combining Taltz (psoriasis treatment) with Zepbound (obesity therapy) led to broader biomarker changes than Taltz alone. The study suggests interconnected immune and metabolic pathways in patients with both psoriasis and obesity. LLY stock closed at $1,169.60, down 1.61%.

Eli Lilly presented new data from a Phase 3b trial showing that the combination of Taltz and Zepbound may benefit obese or overweight psoriasis patients. The company claims the results support a more integrated treatment approach for these patients, addressing both immunological and metabolic aspects. According to Lilly, psoriasis and obesity often coexist in 61% of U.S. patients.

Eli Lilly's experimental drug, retatrutide, helped Type 2 diabetes patients lose 20.8% of their body weight in an 80-week trial. The highest dose group saw an average weight reduction of 49.6 pounds. The drug also improved blood sugar control, with 40% of participants on the two highest doses achieving normal blood sugar levels. The results were presented at the European Association for the Study of Diabetes meeting and published in The Lancet.